TrojanBio

Executive Summary

TrojanBio is a preclinical Israeli biotech pioneering an AI-driven platform to design bispecific antibodies that trick the immune system into attacking tumors as if they were viral infections. By combining a tumor-targeting arm with a viral-mimicry module, the company aims to convert solid tumors into virally infected cells, thereby redirecting potent anti-viral T-cell responses against cancer. Founded in 2020 and based in Rehovot, TrojanBio operates in the intersection of oncology and immunology, with a focus on hard-to-treat solid tumors. The platform leverages computational design to optimize antibody architecture, potentially offering a novel therapeutic approach with built-in immune activation. While still in early preclinical stages, the company has no disclosed funding or valuation data, reflecting its nascent status. Key risks include technical validation of the viral-mimicry concept in vivo, competition from other bispecific and immune-oncology modalities, and the need for significant capital to advance into IND-enabling studies. Success hinges on generating compelling preclinical proof-of-concept data that demonstrates selective tumor cell killing via anti-viral immune activation.

Upcoming Catalysts (preview)

• Q4 2026Preclinical in vivo efficacy data for lead candidate40% success
• Q2 2027Series A financing or strategic partnership50% success
• Q1 2028IND-enabling studies initiation for lead candidate30% success